METHODS Available PLT counts (x10A9/L) from 24 weeks after the last treatment up to the latest counts prior to cirrhosis-related

complications were collected in an international cohort of consecutive patients with chronic HCV infection and advanced hepatic fibrosis (Ishak 4-6) who started interferon-based therapy between BI-2536 1990 and 2003. Repeated measurement analysis with a random intercept and slope per patient and an unstructured covariance matrix was used to analyze PLT over time, correcting for potential non-linearity. Data are presented as median (interquartile range). RESULTS In total 464 patients were included; 321(69%) patients were male, median age was 51 (44-57) years, and 353 (76%) had cirrhosis. SVR was attained by 187 (40%) patients. Pre-treatment PLT were 162 (132-205) in the group with SVR and 142 (100-191) in the group without SVR (p<0.001). Last PLT were measured 5.7 (2.1-7.6) years after SVR, at which time PLT had increased by 35 (7-62; p<0.001).

In those with thrombocytopenia pre-treatment, PLT were >150 in 44 (62%) patients with SVR at last follow-up (p<0.001). In the group without SVR, the last PLT were measured after 4.4 (1.9-7.1) years and had decreased buy NVP-LDE225 by 17 (−5-47, p<0.001). Repeated measurement analysis, including 3387 PLT measurements (interval: 0.45 [0.13-0.79] years), indicated a gradual increase in PLT following SVR and a decline in patients without SVR (p<0.001). CONCLUSION Among patients with HCV-induced advanced hepatic fibrosis the PLT gradually increase following SVR, suggesting liver histology improves with time after eradication of HCV. Disclosures: Adriaan J. van der Meer - Speaking and Teaching: MSD Bart J. Veldt - Board Membership: GSK Jordan J. Feld - Advisory Committees or Review Panels: Roche, Merck, Vertex, Gilead, Abbott, Tibotec, Theravance, Achillion; Speaking and Teaching: Merck, Roche,

Abbott Heiner Wedemeyer – Advisory Committees or Review Panels: Transgene, MSD, Roche, Gilead, Abbott, BMS, Falk; Grant/Research Support: MSD, Novartis, Gilead, Roche, Abbott; Speaking and Teaching: BMS, MSD, Novartis, IĪF Jean-Francois Dufour – Advisory Committees or Review Clomifene Panels: Bayer, BMS, Gilead, Jansse, Novartis, Roche Michael P. Manns – Consulting: Roche, BMS, Gilead, Boehringer Ingelheim, Novartis, Idenix, Achillion, GSK, Merck/MSD, Janssen, Medgenics; Grant/Research Support: Merck/MSD, Roche, Gilead, Novartis, Boehringer Ingelheim, BMS; Speaking and Teaching: Merck/MSD, Roche, BMS, Gilead, Janssen, GSK, Novartis Stefan Zeuzem – Consulting: Abbvie, Achillion Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Gilead, Novartis Pharmaceuticals, Merck & Co., Idenix, Janssen, Roche Pharma AG, Vertex Pharmaceuticals, Presidio, Santaris, Inc Robert J. de Knegt – Advisory Committees or Review Panels: MSD, Roche, Norgine, Janssen Cilag; Grant/Research Support: Gilead, MSD, Roche, Janssen Cilag, BMS; Speaking and Teaching: Gilead, MSD, Roche, Janssen Cilag Harry L.